Does the media favor BCRX or LXRX?

In the previous week, BioCryst Pharmaceuticals had 2 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 4 mentions for BioCryst Pharmaceuticals and 2 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 1.25 beat BioCryst Pharmaceuticals' score of 0.79 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lexicon Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ZBIO or LXRX?

In the previous week, Zenas BioPharma had 2 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 4 mentions for Zenas BioPharma and 2 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 1.25 beat Zenas BioPharma's score of 0.00 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lexicon Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LXRX or INVA?

In the previous week, Innoviva had 1 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 3 mentions for Innoviva and 2 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 1.25 beat Innoviva's score of 1.11 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexicon Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Innoviva 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LXRX or NVAX?

In the previous week, Novavax had 20 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 22 mentions for Novavax and 2 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 1.25 beat Novavax's score of 0.71 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexicon Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novavax 6 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive

Lexicon Pharmaceuticals (LXRX) Competitors

$2.22 -0.03 (-1.33%)

Closing price 07/10/2026 04:00 PM Eastern

Extended Trading

$2.24 +0.01 (+0.68%)

As of 07/10/2026 07:50 PM Eastern

Compare

LXRX vs. CLDX, BCRX, ZBIO, INVA, and NVAX

Should you buy Lexicon Pharmaceuticals stock or one of its competitors? MarketBeat compares Lexicon Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lexicon Pharmaceuticals include Celldex Therapeutics (CLDX), BioCryst Pharmaceuticals (BCRX), Zenas BioPharma (ZBIO), Innoviva (INVA), and Novavax (NVAX). These companies are all part of the "biotechnology" industry.

How does Lexicon Pharmaceuticals compare to Celldex Therapeutics?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Celldex Therapeutics (NASDAQ:CLDX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

Celldex Therapeutics has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -37.46%. Lexicon Pharmaceuticals' return on equity of -18.64% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%
Celldex Therapeutics	N/A	-50.72%	-46.59%

Lexicon Pharmaceuticals presently has a consensus price target of $4.55, indicating a potential upside of 104.95%. Celldex Therapeutics has a consensus price target of $49.30, indicating a potential upside of 26.05%. Given Lexicon Pharmaceuticals' higher probable upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are held by company insiders. Comparatively, 5.2% of Celldex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Lexicon Pharmaceuticals has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

Lexicon Pharmaceuticals has higher revenue and earnings than Celldex Therapeutics. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$49.80M	19.80	-$50.34M	-$0.07	N/A
Celldex Therapeutics	$1.54M	1,993.34	-$258.76M	-$4.26	N/A

In the previous week, Lexicon Pharmaceuticals had 1 more articles in the media than Celldex Therapeutics. MarketBeat recorded 2 mentions for Lexicon Pharmaceuticals and 1 mentions for Celldex Therapeutics. Lexicon Pharmaceuticals' average media sentiment score of 1.25 beat Celldex Therapeutics' score of 0.00 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Lexicon Pharmaceuticals	Positive
Celldex Therapeutics	Neutral

Summary

Lexicon Pharmaceuticals beats Celldex Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Lexicon Pharmaceuticals compare to BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

BioCryst Pharmaceuticals has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market.

Lexicon Pharmaceuticals has a net margin of -37.46% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Lexicon Pharmaceuticals' return on equity of -18.64% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%

BioCryst Pharmaceuticals currently has a consensus target price of $21.78, suggesting a potential upside of 108.40%. Lexicon Pharmaceuticals has a consensus target price of $4.55, suggesting a potential upside of 104.95%. Given BioCryst Pharmaceuticals' higher probable upside, equities research analysts clearly believe BioCryst Pharmaceuticals is more favorable than Lexicon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

BioCryst Pharmaceuticals has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84M	3.04	$263.86M	-$1.78	N/A
Lexicon Pharmaceuticals	$49.80M	19.80	-$50.34M	-$0.07	N/A

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are owned by insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, BioCryst Pharmaceuticals had 2 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 4 mentions for BioCryst Pharmaceuticals and 2 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 1.25 beat BioCryst Pharmaceuticals' score of 0.79 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexicon Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lexicon Pharmaceuticals beats BioCryst Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Lexicon Pharmaceuticals compare to Zenas BioPharma?

Zenas BioPharma (NASDAQ:ZBIO) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 22.0% of Zenas BioPharma shares are owned by insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Zenas BioPharma had 2 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 4 mentions for Zenas BioPharma and 2 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 1.25 beat Zenas BioPharma's score of 0.00 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lexicon Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zenas BioPharma has a beta of -0.96, suggesting that its share price is 196% less volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

Zenas BioPharma presently has a consensus target price of $44.29, suggesting a potential upside of 54.09%. Lexicon Pharmaceuticals has a consensus target price of $4.55, suggesting a potential upside of 104.95%. Given Lexicon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Zenas BioPharma has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -37.46%. Lexicon Pharmaceuticals' return on equity of -18.64% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-99.99%	-58.06%
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%

Lexicon Pharmaceuticals has higher revenue and earnings than Zenas BioPharma. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	$10M	181.44	-$377.74M	-$8.47	N/A
Lexicon Pharmaceuticals	$49.80M	19.80	-$50.34M	-$0.07	N/A

Summary

Lexicon Pharmaceuticals beats Zenas BioPharma on 11 of the 17 factors compared between the two stocks.

How does Lexicon Pharmaceuticals compare to Innoviva?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk.

In the previous week, Innoviva had 1 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 3 mentions for Innoviva and 2 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 1.25 beat Innoviva's score of 1.11 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexicon Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Innoviva	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lexicon Pharmaceuticals has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market. Comparatively, Innoviva has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market.

74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.1% of Innoviva shares are owned by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are owned by insiders. Comparatively, 2.0% of Innoviva shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Lexicon Pharmaceuticals currently has a consensus target price of $4.55, indicating a potential upside of 104.95%. Innoviva has a consensus target price of $36.20, indicating a potential upside of 62.77%. Given Lexicon Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Lexicon Pharmaceuticals is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Innoviva has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$49.80M	19.80	-$50.34M	-$0.07	N/A
Innoviva	$411.33M	3.99	$271.17M	$6.01	3.70

Innoviva has a net margin of 119.89% compared to Lexicon Pharmaceuticals' net margin of -37.46%. Innoviva's return on equity of 33.33% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%
Innoviva	119.89%	33.33%	22.67%

Summary

Innoviva beats Lexicon Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Lexicon Pharmaceuticals compare to Novavax?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. Comparatively, 53.0% of Novavax shares are owned by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are owned by insiders. Comparatively, 1.6% of Novavax shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Novavax has higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$49.80M	19.80	-$50.34M	-$0.07	N/A
Novavax	$1.12B	1.37	$440.30M	-$0.58	N/A

Lexicon Pharmaceuticals has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, Novavax has a beta of 2.43, suggesting that its stock price is 143% more volatile than the broader market.

Novavax has a net margin of -14.73% compared to Lexicon Pharmaceuticals' net margin of -37.46%. Novavax's return on equity of -14.82% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%
Novavax	-14.73%	-14.82%	1.23%

Lexicon Pharmaceuticals presently has a consensus price target of $4.55, suggesting a potential upside of 104.95%. Novavax has a consensus price target of $13.00, suggesting a potential upside of 39.34%. Given Lexicon Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Lexicon Pharmaceuticals is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.40

In the previous week, Novavax had 20 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 22 mentions for Novavax and 2 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 1.25 beat Novavax's score of 0.71 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexicon Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novavax	6 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

Summary

Novavax beats Lexicon Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Lexicon Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LXRX vs. The Competition

Export

Metric	Lexicon Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$999.44M	$3.79B	$7.12B	$12.61B
Dividend Yield	N/A	2.17%	2.68%	7.83%
P/E Ratio	-31.71	21.27	27.19	24.56
Price / Sales	19.80	323.90	590.19	121.71
Price / Cash	N/A	147.64	49.34	60.04
Price / Book	7.40	8.41	10.90	6.39
Net Income	-$50.34M	$23.85M	$3.57B	$331.44M
7 Day Performance	-4.31%	-0.76%	-0.25%	0.37%
1 Month Performance	17.46%	8.80%	4.53%	0.54%
1 Year Performance	105.56%	53.61%	29.18%	21.93%

Lexicon Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LXRX Lexicon Pharmaceuticals	2.3989 of 5 stars	$2.22 -1.3%	$4.55 +105.0%	+96.5%	$999.44M	$49.80M	N/A	140	Positive News Analyst Downgrade
CLDX Celldex Therapeutics	1.7976 of 5 stars	$37.95 -1.1%	$49.30 +29.9%	+72.4%	$3.01B	$1.54M	N/A	150
BCRX BioCryst Pharmaceuticals	3.1318 of 5 stars	$10.17 +3.4%	$21.67 +113.0%	+17.7%	$2.50B	$874.84M	N/A	530	News Coverage Analyst Forecast
ZBIO Zenas BioPharma	3.1653 of 5 stars	$26.45 -2.9%	$44.29 +67.4%	+138.1%	$1.72B	$10M	N/A	N/A	News Coverage Analyst Downgrade
INVA Innoviva	3.6625 of 5 stars	$21.82 -2.2%	$36.20 +65.9%	+16.7%	$1.65B	$411.33M	3.63	100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LXRX) was last updated on 7/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lexicon Pharmaceuticals (LXRX) Competitors

LXRX vs. CLDX, BCRX, ZBIO, INVA, and NVAX

How does Lexicon Pharmaceuticals compare to Celldex Therapeutics?

Summary

How does Lexicon Pharmaceuticals compare to BioCryst Pharmaceuticals?

Summary

How does Lexicon Pharmaceuticals compare to Zenas BioPharma?

Summary

How does Lexicon Pharmaceuticals compare to Innoviva?

Summary

How does Lexicon Pharmaceuticals compare to Novavax?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXRX vs. The Competition

Lexicon Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lexicon Pharmaceuticals (LXRX) Competitors

LXRX vs. CLDX, BCRX, ZBIO, INVA, and NVAX

How does Lexicon Pharmaceuticals compare to Celldex Therapeutics?

Is LXRX or CLDX more profitable?

Do analysts prefer LXRX or CLDX?

Do insiders & institutionals have more ownership in LXRX or CLDX?

Which has more risk & volatility, LXRX or CLDX?

Which has higher earnings and valuation, LXRX or CLDX?

Does the media favor LXRX or CLDX?

Summary

How does Lexicon Pharmaceuticals compare to BioCryst Pharmaceuticals?

Which has more volatility and risk, BCRX or LXRX?

Is BCRX or LXRX more profitable?

Do analysts prefer BCRX or LXRX?

Which has better valuation and earnings, BCRX or LXRX?

Do insiders & institutionals hold more shares of BCRX or LXRX?

Does the media favor BCRX or LXRX?

Summary

How does Lexicon Pharmaceuticals compare to Zenas BioPharma?

Do institutionals & insiders believe in ZBIO or LXRX?

Does the media refer more to ZBIO or LXRX?

Which has more risk and volatility, ZBIO or LXRX?

Do analysts rate ZBIO or LXRX?

Is ZBIO or LXRX more profitable?

Which has preferable valuation & earnings, ZBIO or LXRX?

Summary

How does Lexicon Pharmaceuticals compare to Innoviva?

Does the media prefer LXRX or INVA?

Which has more risk and volatility, LXRX or INVA?

Do institutionals and insiders have more ownership in LXRX or INVA?

Do analysts recommend LXRX or INVA?

Which has better valuation and earnings, LXRX or INVA?

Is LXRX or INVA more profitable?

Summary

How does Lexicon Pharmaceuticals compare to Novavax?

Do institutionals & insiders hold more shares of LXRX or NVAX?

Which has preferable earnings & valuation, LXRX or NVAX?

Which has more volatility and risk, LXRX or NVAX?

Is LXRX or NVAX more profitable?

Do analysts prefer LXRX or NVAX?

Does the media prefer LXRX or NVAX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXRX vs. The Competition

Lexicon Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools